• Baricitinib and PSC: From Space to Causality

  2026-10-08

  Baricitinib (LY3009104) offers a selective pharmacological lens for interpreting JAK-STAT activity suggested by spatial proteomics in primary sclerosing cholangitis. This article separates reported evidence from mechanistic inference and explains how JAK1/2 inhibition can test, but not by itself prove, IL-6 or IL-23 pathway dependence.

• Telatinib (BAY 57-9352): Five Evidence Questions

  2026-10-08

  A source-grounded overview of Telatinib research, covering kinase targets, the 2026 TNBC study, evidence strength, interpretation, and limits on applicability.

• Lysosomal β-Galactosidase in Senescence Research

  2026-10-07

  A source-grounded overview of lysosomal β-galactosidase staining, its interpretation as a control readout in cellular senescence research, and the reported relationship between SLC25A1, senescence, and cisplatin resistance in HNSCC.

• SpCas9 mRNA in LOXHD1b Zebrafish Research

  2026-10-07

  A source-grounded overview of how SpCas9 mRNA relates conceptually to CRISPR-Cas9 modeling of LOXHD1b-associated hair-cell dysfunction, with emphasis on published findings, evidence strength, provenance, and translational limitations.

• Heparin Sodium and Testicular Nanovesicle Research

  2026-10-06

  A source-grounded overview of how a 2025 preprint links Cistanche deserticola-derived nanovesicles with Sertoli-cell protection, and where heparin sodium may fit conceptually as a glycosaminoglycan research comparator rather than an established intervention.

• 5X Protein Loading Buffer (Reducing): Overview

  2026-10-06

  APExBIO’s SKU K1164 is a supplier-described 5X reducing protein loading buffer for conventional SDS-PAGE sample preparation. No matched paper evidence was provided, so performance claims and broader applicability remain unverified.

• RP3-340N1.2 Stabilizes IL-6 mRNA in NSCLC

  2026-10-05

  The reference study links the long non-coding RNA RP3-340N1.2 to NSCLC proliferation, migration, and tumor-associated macrophage effects through post-transcriptional stabilization of IL-6 mRNA. Its combination of RNA sequencing, functional perturbation, mRNA-decay analysis, and RNA immunoprecipitation provides a mechanistic framework for studying lncRNA–RNA-binding protein interactions in cancer biology.

• UBR1 and UBR2 in Mammalian ER Stress Sensing

  2026-10-05

  The 2024 study identifies the E3 ligases UBR1 and UBR2 as previously underappreciated components of mammalian endoplasmic reticulum protein quality control. Its findings connect N-degron biology with ER stress adaptation, showing that loss of either factor increases sensitivity to stress-induced apoptosis while stress conditions stabilize both proteins.

• In Situ CAR-M Design for Hepatocellular Carcinoma

  2026-10-04

  Li and colleagues report an in situ CAR-macrophage strategy that combines GPC3 recognition with IFN-γ signaling and a dominant-negative SIRPα extracellular domain to strengthen macrophage activity against hepatocellular carcinoma. In mouse models and human HCC organoid systems, the design promoted inflammatory tumor-microenvironment remodeling and phagocytosis, although its evidence remains preclinical and requires validation in more clinically representative settings.

• FDA-Approved Drugs Against MERS-CoV: Lopinavir Evidence

  2026-10-02

  de Wilde and colleagues screened 348 FDA-approved compounds in cell culture and identified chloroquine, chlorpromazine, loperamide, and Lopinavir as inhibitors of MERS-CoV replication. The study provides a practical repurposing framework for emerging coronavirus research, while its low-micromolar activity data also clarify why Lopinavir requires mechanistic, cytotoxicity, and in vivo validation before conclusions about clinical utility.

• AMG 9810: Selective TRPV1 Antagonist Guide

  2026-10-01

  AMG 9810 is a selective competitive TRPV1 antagonist for mechanistic studies of capsaicin, heat, proton, and endogenous-ligand signaling. Its reported nanomolar activity in human and rat TRPV1 systems supports calcium-flux, CGRP-release, sensory-neuron, and pain-mechanism research.

• TRPV1+ Somatosensory Nerves and Inflammation

  2026-10-01

  Song et al. show that targeted stimulation of TRPV1+ peripheral afferents at the nape suppresses systemic inflammation through a coordinated somato-autonomic reflex. The work connects sensory nerve activation with brainstem, endocrine, autonomic, and splenic immune regulation, providing a mechanistic framework for neuroimmune intervention studies.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-30

  This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in ovalbumin-sensitized rats by integrating behavioral, histological, immune, molecular, and intestinal microbiota measurements. Its main contribution is a gut–nasal immune framework in which treatment-associated microbiota shifts and increased short-chain fatty acids accompany reduced allergic inflammation, although the findings remain preclinical and do not establish causality.

• Platelet Extravasation into Tumors: CXCR4 Control

  2026-09-30

  The reference study defines platelet transendothelial migration into tumors as a regulated, CXCL12/CXCR4-dependent process rather than passive vascular leakage. Its genetic, pharmacologic, and imaging data separate platelet trafficking from granule-mediated tumor growth effects and identify FAK, PECAM-1, Munc13-4, Munc18-2, and CLEC-2/podoplanin as distinct control points.

• Diuron Workflows for Plant and Toxicology Research

  2026-09-29

  Use Diuron as a controlled photosynthesis inhibitor for plant biology research and as a mechanistic probe in renal toxicology. This workflow connects dose-controlled exposure, HK-2 cell phenotyping, and JAK2/STAT1-focused validation while addressing solubility, storage, and assay reproducibility.

7834 records 1/523 page Next 12345 下5页 Last page